Tiragolumab
- Generic Name
- Tiragolumab
- Drug Type
- Biotech
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT05908786
- Locations
- 🇫🇷
Centre Eugene Marquis (CEM), Rennes, France
🇫🇷Gustave Roussy, Villejuif CEDEX, France
🇩🇪University Essen, Essen, Germany
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 650
- Registration Number
- NCT05904886
- Locations
- 🇧🇪
AZ Delta (Campus Rumbeke), Roeselare, Belgium
🇧🇷Oncoclínicas do Brasil - BELO HORIZONTE, Belo Horizonte, Minas Gerais, Brazil
🇰🇷Ulsan University Hosiptal, Ulsan, Korea, Republic of
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05862285
- Locations
- 🇨🇷
Clinica CIMCA, San José, Costa Rica
🇧🇪GHdC Site Les Viviers, Charleroi, Belgium
🇧🇪AZ Groeninge, Kortrijk, Belgium
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 35
- Registration Number
- NCT05825625
- Locations
- 🇩🇪
Thoraxklinik Heidelberg, Heidelberg, Germany
🇩🇪Universitätsklinikum Essen (AöR)-Westdeutsches Tumorzentrum Essen, Essen, Germany
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 199
- Registration Number
- NCT05805501
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇫🇷CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France
🇫🇷Centre Francois Baclesse, Caen, France
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 178
- Registration Number
- NCT05798663
- Locations
- 🇺🇸
Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸Kaiser Permanente Roseville Medical Center, Roseville, California, United States
🇺🇸Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 3
- Registration Number
- NCT05746481
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05743504
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
- Conditions
- Advanced Rare Malignant Solid NeoplasmRare Malignant Solid NeoplasmRefractory Rare Malignant Solid Neoplasm
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography Test
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT05715281
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients with Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
- Conditions
- Squamous Cell CarcinomaOral Cavity Squamous Cell Carcinoma
- Interventions
- Behavioral: Standard of CareBehavioral: QuestionnairesRadiation: CisplatinRadiation: Carboplatin
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT05681039
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.